Earnings ·
Kiniksa Pharmaceuticals International, plc reported second quarter 2026 financial results, posting net product revenue…
KNSAKiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc reported second quarter 2026 financial results, posting net product revenue of $243.6 million, a 55% increase from the prior year period. The company raised its full-year 2026 ARCALYST net product revenue guidance to $980–$995 million, up from the previous range of $930–$945 million. Net income for the quarter was $25.4 million, compared to $17.8 million in the same period last year. The firm also announced that its pivotal Phase 3 trial for KPL-387, PASTORALE, has begun enrolling and dosing patients for recurrent pericarditis. Kiniksa operates in the biopharmaceutical industry, developing and commercializing novel therapies for cardiovascular and inflammatory diseases.